BioCentury | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BioCentury | Dec 15, 2017
Financial News

Aelin raises €27M in series A

On Dec. 11, Aelin Therapeutics N.V. (Leuven, Belgium) debuted with a €27 million ($31.8 million) series A round from LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+. Aelin spun out of the...
BioCentury | Dec 11, 2017
Financial News

VIB spinout Aelin raises €27M in series A

Aelin Therapeutics N.V. (Leuven, Belgium) debuted with a €27 million ($31.8 million) series A round from LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+. Aelin spun out of the Flanders Institute for...
BioCentury | Sep 3, 2015
Distillery Therapeutics

Therapeutics: Solute carrier family 15 H+ peptide transporter member 2 (SLC15A2; PEPT2)

...patient sample studies suggest inhibiting SLC15A2 could help treat CML. Levels of the dipeptide transporter SLC15A2...
...were higher in bone marrow samples from CML patients than healthy controls, and levels of SLC15A2...
...CML and other cancers. TARGET/MARKER/PATHWAY: Solute carrier family 15 H+ peptide transporter member 2 (SLC15A2; PEPT2...
BioCentury | Feb 28, 2013
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Systemic lupus erythematosus (SLE) Solute carrier family 15 member 4 (SLC15A4; PHT1) Mouse studies suggest antagonizing SLC15A4 could help treat SLE. In a mouse...
BioCentury | Dec 4, 2008
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Cadherin-like 24 (CDH24); solute carrier family 15 (oligopeptide transporter), member 1 (SLC15A); kinase non-catalytic C-lobe domain (KIND)...
BioCentury | Aug 28, 2008
Targets & Mechanisms

Curbing Mitochondrial Appetite

Several companies have tried and failed to develop obesity drugs that agonize mitochondrial uncoupling proteins, which let adipose cells generate heat by burning excess fat. A new study now suggests that one member of this...
BioCentury | Jun 30, 1997
Finance

A week to forget

Biotech stocks survived relatively unscathed last week despite a spate of truly bad news. One FDA panel's recommendation for approval of Neurex's Corlopam hypertension treatment on Thursday was not enough to buoy the biotech market...
Items per page:
1 - 8 of 8